PURPOSE: This study evaluated the sensitivity of a 3.0-Tesla (T) magnetic resonance imaging (MRI) in measuring cerebral phenylalanine using proton magnetic resonance spectroscopy and in assessing MR-documented white-matter changes by means of diffusion studies (diffusion-weighted imaging, apparent diffusion coefficient map; diffusion tensor imaging) in patients with phenylketonuria. MATERIALS AND METHODS: Thirty-two patients with the classical clinical and biochemical deficits of phenylketonuria underwent biochemical (blood phenylalanine), genotypic (phenylalanine hydroxylase gene) and radiological investigation by means of MRI, proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging with a 3.0-T scanner. RESULTS: Periventricular and subcortical white-matter changes were detected on all MR scans. In 29/32 patients, proton magnetic resonance spectroscopy easily documented abnormal signal elevation at 7.36 ppm, corresponding to phenylalanine, despite its low concentration. Phenylalanine signal amplitude relative to the creatine/phosphocreatine signal increased linearly with blood phenylalanine values (r 0.7067; p<0.001). Diffusion MRI demonstrated hyperintensity in the areas exhibiting MRI changes as well as decreased apparent diffusion coefficient values, but fractional anisotropy indices were normal. CONCLUSIONS: The high signal, together with better spectral, spatial, contrast and temporal resolution, makes the 3.0-T MR the most suitable technique in the study of the phenylketonuria. In particular, the multimodal approach with MRI, proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging can provide more information than previous studies performed with low-field systems.
PURPOSE: This study evaluated the sensitivity of a 3.0-Tesla (T) magnetic resonance imaging (MRI) in measuring cerebral phenylalanine using proton magnetic resonance spectroscopy and in assessing MR-documented white-matter changes by means of diffusion studies (diffusion-weighted imaging, apparent diffusion coefficient map; diffusion tensor imaging) in patients with phenylketonuria. MATERIALS AND METHODS: Thirty-two patients with the classical clinical and biochemical deficits of phenylketonuria underwent biochemical (blood phenylalanine), genotypic (phenylalanine hydroxylase gene) and radiological investigation by means of MRI, proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging with a 3.0-T scanner. RESULTS: Periventricular and subcortical white-matter changes were detected on all MR scans. In 29/32 patients, proton magnetic resonance spectroscopy easily documented abnormal signal elevation at 7.36 ppm, corresponding to phenylalanine, despite its low concentration. Phenylalanine signal amplitude relative to the creatine/phosphocreatine signal increased linearly with blood phenylalanine values (r 0.7067; p<0.001). Diffusion MRI demonstrated hyperintensity in the areas exhibiting MRI changes as well as decreased apparent diffusion coefficient values, but fractional anisotropy indices were normal. CONCLUSIONS: The high signal, together with better spectral, spatial, contrast and temporal resolution, makes the 3.0-T MR the most suitable technique in the study of the phenylketonuria. In particular, the multimodal approach with MRI, proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging can provide more information than previous studies performed with low-field systems.
Authors: Setsu Wakana; Hangyi Jiang; Lidia M Nagae-Poetscher; Peter C M van Zijl; Susumu Mori Journal: Radiology Date: 2003-11-26 Impact factor: 11.105
Authors: Alfonso Di Costanzo; F Trojsi; M Tosetti; G M Giannatempo; F Nemore; M Piccirillo; S Bonavita; G Tedeschi; T Scarabino Journal: Eur J Radiol Date: 2003-11 Impact factor: 3.528
Authors: T Scarabino; T Popolizio; G M Giannatempo; F Nemore; A Maiorana; A Carriero; D Messana; A Maggialetti; M Armillotta; U Salvolini Journal: Radiol Med Date: 2007-02-22 Impact factor: 3.469
Authors: T Scarabino; G M Giannatempo; T Popolizio; M Tosetti; V d'Alesio; F Esposito; F Di Salle; A Di Costanzo; A Bertolino; A Maggialetti; U Salvolini Journal: Radiol Med Date: 2007-02-22 Impact factor: 3.469
Authors: Susumu Mori; Walter E Kaufmann; Christos Davatzikos; Bram Stieltjes; Laura Amodei; Kim Fredericksen; Godfrey D Pearlson; Elias R Melhem; Meiyappan Solaiyappan; Gerald V Raymond; Hugo W Moser; Peter C M van Zijl Journal: Magn Reson Med Date: 2002-02 Impact factor: 4.668
Authors: P A McCombe; D B McLaughlin; J B Chalk; N N Brown; J J McGill; M P Pender Journal: J Neurol Neurosurg Psychiatry Date: 1992-05 Impact factor: 10.154
Authors: J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; E Harms; H E Möller Journal: Ann Neurol Date: 2001-10 Impact factor: 10.422
Authors: V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino Journal: J Inherit Metab Dis Date: 2007-01-23 Impact factor: 4.750
Authors: A Stecco; F Fabbiano; P Amatuzzo; E Cignini; M Brambilla; L Masini; M Krengli; A Carriero Journal: Radiol Med Date: 2012-08-08 Impact factor: 3.469
Authors: Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White Journal: Mol Genet Metab Date: 2014-11-13 Impact factor: 4.797
Authors: Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White Journal: Mol Genet Metab Date: 2013-04-06 Impact factor: 4.797
Authors: Desirée A White; Jo Ann V Antenor-Dorsey; Dorothy K Grange; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Shawn E Christ Journal: Mol Genet Metab Date: 2013-07-19 Impact factor: 4.797